Patient
|
Menopause status
|
Histologic type
|
Histological grading
|
B classification
|
MIB-1 [%]
|
Receptor status
|
Molecular subtype
|
---|
ER
|
PR
|
HER2/neu
|
---|
1
|
Post
|
IDC
|
G2
|
B5b
|
10
|
+++
|
++
|
−
|
Luminal A
|
2
|
Post
|
IDC
|
G2
|
B5b
|
10
|
+++
|
++
|
−
|
Luminal A
|
3
|
Peri
|
IDC
|
G3
|
B5b
|
30
|
+++
|
−
|
−
|
Luminal A
|
4
|
Pre
|
IDC
|
G2
|
B5b
|
40
|
+++
|
++
|
+++
|
Luminal B
|
5
|
Post
|
IDC
|
G2
|
B5b
|
60
|
+++
|
++
|
−
|
Luminal A
|
6
|
Pre
|
IDC
|
G3
|
B5b
|
50
|
+++
|
+++
|
+++
|
Luminal B
|
7
|
Post
|
IDC
|
G3
|
B5b
|
20
|
pos.
|
pos.
|
−
|
Luminal A
|
8
|
Post
|
IDC
|
G2
|
B5b
|
20
|
+++
|
+++
|
−
|
Luminal A
|
9
|
Post
|
IDC
|
G3
|
B5
|
30
|
++
|
+++
|
−
|
Luminal A
|
10
|
Post
|
IDC
|
G3
|
B5b
|
20
|
+++
|
+++
|
+
|
Luminal B
|
11
|
Post
|
IDC
|
G1
|
B5c
|
20
|
+++
|
+++
|
+
|
Luminal B
|
12
|
Post
|
IDC
|
G3
|
B5b
|
70
|
−
|
−
|
−
|
Triple negative
|
13
|
Pre
|
ILC
|
n.s.
|
B5b
|
50
|
+++
|
++
|
−
|
Luminal A
|
14
|
Pre
|
IDC
|
G3
|
B5b
|
80
|
++
|
−
|
−
|
Luminal A
|
15
|
Post
|
IDC
|
G3
|
B5b
|
40
|
+++
|
++
|
−
|
Luminal A
|
16
|
Post
|
ILC
|
G2
|
B5b
|
30
|
+++
|
+++
|
−
|
Luminal A
|
17
|
Pre
|
Mucinous
|
G2
|
B5b
|
50
|
+++
|
++
|
+++
|
Luminal B
|
18
|
Post
|
IDC
|
G3
|
B5b
|
50
|
−
|
−
|
+++
|
HER2/neu
|
-
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, MIB-1 mindbomb E3 ubiquitin protein ligase 1 (proliferative activity), ER estrogen receptor, PR progesterone receptor, HER2/neu human epidermal growth factor receptor 2, n.s. not specified, + weakly positive, ++ moderately positive, +++ strongly positive, − negative